Skip to content
MARKETS / NASDAQ / NNOX
NASDAQ · X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS · MID CAP

Nano-X Imaging Ltd. NNOX

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$13.0M
▲ 15.4% YoY
$-75.0M
$-45.0M
In brief

What this company does

Nanox develops the multi-source Nanox.ARC, a 3D tomosynthesis imaging system that has received two 510(k) clearances from the FDA and remains subject to regulatory clearance and approval in other jurisdictions. Deployment of the systems runs through direct sales and commercial collaborations, with approximately 36 systems in various stages of deployment. Nanox.MARKETPLACE, acquired from MDWEB in November 2021, connects imaging facilities with radiologists and lets radiologists supply, and customers obtain, remote interpretations of imaging data. Teleradiology services are supplied to approximately 100 customers representing approximately 200 facilities, with images allocated to radiologists in the network according to their area of specialization. Manufacture of the MEMs X-ray chips began at the company's fabrication facility in Korea. The X-ray source technology has its roots in field emission display work: in 2011 the predecessor company acquired certain non-display related know-how from FET Japan Inc., and members of that technical team joined the company.

Written from the business description in Nano-X Imaging Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 30 April 2026. Every sentence was checked against that document before publication.

Growth
USD 13.0M
Revenue, FY2025 · full 8-year series below
Revenue $M Net income $M
FY2025 · Revenue 13.0 · Net income -75.0
5M10M-40M-80M20182019202020212022202320242025
Compound annual growth
+14.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−576 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -600.8% · Net -576.1%
-2000%-4000%20182019202020212022202320242025
ROE
FY2025 · ROE -45.6%
-20%-40%20182019202020212022202320242025

Each USD of equity lost 46 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -45.0
-25.0M-50.0M20182019202020212022202320242025

Total assetsUSD 162.2M
EquityUSD 139.7M
CashUSD 49.2M
Gross debtUSD 3.1M
Net debtUSD -46.0M
Current ratio3.96×

The company holds more cash than debt.

The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018
Revenue $B0.00.00.00.00.0···
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0
Income tax $B−0.0−0.0−0.0−0.0−0.0···
Net income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.1−0.1−0.0−0.0−0.0
EPS, diluted $−1.16−0.91−1.08−2.17−1.28−1.23−0.90−0.09
Dividend / sh $········
Payout %········
ROE %−45.6−27.8−29.5−44.5−23.6−39.5··
Shares out B··0.060.060.050.050.03·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 35 reconciliationsAUDITED

Reconciled in 8 of 19 fiscal years. 60 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityX-Ray Apparatus & Tubes & Related Irradiation Apparatus
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2018

Share this section

Download image